J&J Boosts U.S. Investment to $55B Over Four Years
J&J Boosts U.S. Investment to $55B Over Four Years Johnson & Johnson, one of the world’s leading healthcare and pharmaceutical companies, has announced a significant increase in its investment in…
Read MoreJ&J Boosts U.S. Investment to $55B Over Four Years
Johnson & Johnson to Build Advanced Biologics Facility in North Carolina
Johnson & Johnson to Build Advanced Biologics Facility in North Carolina Johnson & Johnson (the “Company”) is set to break ground on a new, cutting-edge biologics manufacturing facility in Wilson,…
AstraZeneca to Invest $2.5B in Beijing R&D, Biotech & Manufacturing
AstraZeneca to Invest $2.5B in Beijing R&D, Biotech & Manufacturing AstraZeneca has announced a major investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre, alongside…
Novartis’ Fabhalta® (iptacopan) Wins Third FDA Approval for C3G
Novartis’ Fabhalta® (iptacopan) Wins Third FDA Approval for C3G Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta® (iptacopan) for the treatment of adults…
Omeros Updates Phase 3 Zaltenibart PNH Trial
Omeros Updates Phase 3 Zaltenibart PNH Trial Omeros Corporation has announced that site activation for enrollment is underway in its Phase 3 clinical trial program evaluating zaltenibart (OMS906) for the…
California University of Science and Medicine Celebrates 2025 MD Match Day
California University of Science and Medicine Celebrates 2025 MD Match Day California University of Science and Medicine (CUSM) proudly announced that its 2025 MD graduating class successfully secured residency placements…
FDA Approves Alnylam’s AMVUTTRA® for ATTR-CM Treatment
FDA Approves Alnylam’s AMVUTTRA® for ATTR-CM Treatment Alnylam Pharmaceuticals, Inc., a pioneer in RNAi therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New…
Pint Pharma Secures ANVISA Approval for BESREMi® in PV Treatment
Pint Pharma Secures ANVISA Approval for BESREMi® in PV Treatment Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment…
Poxel Reports Positive Preclinical Results for PXL065 in HCM
Poxel Reports Positive Preclinical Results for PXL065 in HCM POXEL SA, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases with metabolic pathophysiology, including metabolic…
Verastem Oncology Q4 & Full-Year 2024 Results, Business Updates
Verastem Oncology Q4 & Full-Year 2024 Results, Business Updates Verastem Oncology, a biopharmaceutical company dedicated to developing innovative therapies for cancer patients, has announced its financial results for the fourth…
GRM Information Management to Exhibit at USCAP Annual Meeting
GRM Information Management to Exhibit at USCAP Annual Meeting GRM Information Management (GRM) is set to showcase its specialized pathology storage services at the prestigious United States and Canadian Academy…
NeuroSense Moves Closer to Early Canadian ALS Drug Launch
NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug NeuroSense Therapeutics Ltd. has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K…